一种工程化活化凝血因子V用于预防和治疗小鼠急性创伤性凝血病及出血
急性创伤性凝血病(ATC)约占创伤患者的30%并与死亡率增加相关。研究使用两种小鼠模型,探讨对活化蛋白C(APC)灭活具有抵抗性且含稳定A2-A3结构域二硫键的工程化活化FV变体(superFVa)能否减少创伤性出血并纠正ATC的止血参数。结果表明,预防性给予superFVa可预防ATC和创伤性出血,在ATC发展过程中给药可稳定出血并逆转异常止血参数,作者认为superFVa可能是拦截ATC和减轻创伤性出血的有吸引力的策略。
要点
- 创伤合并休克诱导的ATC以APTT延长及FV、FVIII和纤维蛋白原降低为特征。
- 预防性给予superFVa可减少肝撕裂模型出血并预防ATC发展。
- ATC发展过程中给予superFVa可稳定出血并逆转异常止血参数。
核心结论
- 预防性给予superFVa可预防ATC和创伤性出血,在ATC进行中给药可稳定出血并逆转异常止血参数。
- 作者认为superFVa可能是拦截ATC和减轻创伤性出血的有吸引力的策略。
研究设计与样本
- 研究使用两种小鼠模型:创伤合并休克诱导ATC模型和肝撕裂导致严重出血并继发ATC的模型。
主要发现
- 创伤合并休克诱导的ATC以APTT延长及FV、FVIII和纤维蛋白原降低为特征,而因子II和因子X未降低。
- 在创伤合并休克模型中,给予superFVa使APTT正常化,使FV和FVIII凝血活性水平回到正常范围,并降低APC和凝血酶-抗凝血酶(TAT)水平。
- 在肝撕裂模型中,肝撕裂前预防性给予superFVa减少出血,并预防APTT延长、FV和FVIII耗竭及APC过度生成。
- 在肝撕裂模型中,ATC发展后开始给予superFVa可稳定出血、逆转延长的APTT、使FV和FVIII水平回到正常范围,并降低被ATC升高的TAT水平。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute traumatic coagulopathy (ATC) occurs in approximately 30% of patients with trauma and is associated with increased mortality. Excessive generation of activated protein C (APC) and hyperfibrinolysis are believed to be driving forces for ATC. Two mouse models were used to investigate whether an engineered activated FV variant (superFVa) that is resistant to inactivation by APC and contains a stabilizing A2-A3 domain disulfide bond can reduce traumatic bleeding and normalize hemostasis parameters in ATC. First, ATC was induced by the combination of trauma and shock. ATC was characterized by activated partial thromboplastin time (APTT) prolongation and reductions of factor V (FV), factor VIII (FVIII), and fibrinogen but not factor II and factor X. Administration of superFVa normalized the APTT, returned FV and FVIII clotting activity levels to their normal range, and reduced APC and thrombin-antithrombin (TAT) levels, indicating improved hemostasis. Next, a liver laceration model was used where ATC develops as a consequence of severe bleeding. superFVa prophylaxis before liver laceration reduced bleeding and prevented APTT prolongation, depletion of FV and FVIII, and excessive generation of APC. Thus, prophylactic administration of superFVa prevented the development of ATC. superFVa intervention started after the development of ATC stabilized bleeding, reversed prolonged APTT, returned FV and FVIII levels to their normal range, and reduced TAT levels that were increased by ATC. In summary, superFVa prevented ATC and traumatic bleeding when administered prophylactically, and superFVa stabilized bleeding and reversed abnormal hemostasis parameters when administered while ATC was in progress. Thus, superFVa may be an attractive strategy to intercept ATC and mitigate traumatic bleeding.
引用
- Joseph BC, Miyazawa BY, Esmon CT, et al. An engineered activated factor V for the prevention and treatment of acute traumatic coagulopathy and bleeding in mice. Blood Adv. 2022. PMID: 34861695. doi:10.1182/bloodadvances.2021005257
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。